Gemini Therapeutics, Inc.
3 clinical trials · Sponsor
◉ Watch Gemini Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration (NCT04684394) | Gemini Therapeutics, Inc. | 2020-12-29 |
| A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration (NCT04643886) | Gemini Therapeutics, Inc. | 2020-07-30 |
| First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration (NCT04246866) | Gemini Therapeutics, Inc. | 2019-12-19 |
Track Gemini Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.